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Rationale: Cervical dystonia is the most common form of (primary) dystonia. The ﬁrst line of treatment
for cervical dystonia is intramuscular injections with botulinum toxin. To optimise the response to
botulinum toxin proper muscles selection is required. Pre-treatment polymyographic EMG in addition to
clinical evaluation is hypothesised to be a good tool to improve muscle selection and treatment outcome.
Objective: To determine the efﬁcacy of botulinum toxin treatment after adjacent polymyographic EMG in
cervical dystonia patients referred to our tertiary referral centre with an unsatisfactory response to
botulinum toxin treatment elsewhere.
Methods: We performed a retrospective analysis of 40 consecutive second opinion cervical dystonia
patients. Standard polymyographic EMG was performed before treatment. We retrieved the Tsui scores
and subjective evaluations from the ﬁrst visit, after 12 weeks and after one year of treatment. In addition,
we assessed the ﬁnal outcome of treatment in our centre based on the records and asked the patients for
their personal opinion about the effect of referral to our centre on their treatment response.
Results: After one year of treatment there was a signiﬁcant improvement on both the Tsui scores
(p < 0.01) and the subjective treatment evaluation (p < 0.001.) On their last visit 60% of the patients still
continued treatment with a reasonable to good response.
Conclusion: A substantial amount of CD patients with an unsatisfactory response to botulinum toxin
improved after polymyography and subsequent treatment with botulinum toxin in a tertiary referral
centre.
 2013 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
Dystonia is a syndrome characterized by sustained involuntary
muscle contractions leading to debilitating abnormal postures, pain
and twisting movements. Cervical dystonia (CD), also called spas-
modic torticollis, is the most common form of (primary) dystonia
[1e3]. In simple rotational torticollis, the most frequent dystonic
posture in CD, the sternocleidomastoid (SCM), the splenius capitis
(SPL) and the obliquus capitis (OC) muscles are typically involved.
In more complex movements, such as laterocollis, antecollis, ret-
rocollis, and tremulous torticollis, other combinations of muscles
are active [4e6].
The ﬁrst line of treatment for CD is intramuscular injections
with botulinum toxin (BoNT) in the dystonic muscles. BoNTþ31 50 3611707.
. Nijmeijer), M.A.J.de.Koning-
evier OA license.treatment results in signiﬁcant improvement of resting posture and
reduction of pain in about 85% of the patients [7,8].
The supposedly most important determinants of a favourable
response to BoNT treatment include proper selection of dystonic
muscles and an appropriate dosage of BoNT [9]. The selection
of muscles to be injected with BoNT is usually based on clinical
features, such as abnormal posture, muscle palpation, muscle hy-
pertrophy, and pain. In addition to clinical examination, polymyo-
graphic electromyography (pEMG) can be used to determine the
pattern of muscle involvement. Some studies indicate that
pEMG for muscle selection may help to improve the response to
botulinum toxin treatment, but evidence is scarce [10]. The
Academic Medical Center (AMC) is a national reference centre for
patients with dystonia in the Netherlands. Many CD patients with
an unsatisfactory response to botulinum toxin treatment are
referred to our outpatient clinic. Before treatment, all patients
undergo pEMG. Based on the clinical evaluation combined with
pEMG results patients are treated with botulinum toxin injections.
To determine the efﬁcacy of referral to our tertiary referral centre
Table 1
Baseline characteristics.
Male 14/40 (35%)
Age 56 years (mean, SD: 11.9)
Disease duration 7.5 years (median, IQR: 2.25e13.75)
Number of previous treatments 5 (median, IQR: 2e14)
Baseline Tsui (0e25 points) 11.2 (mean, SD: 3.1)
Baseline VAS (0e10 points) 8.2 (mean, SD: 1.15)
Dosage (last in referring centre) 375 MU (median, IQR 285e500)
Primary non-responders 69%
SD: standard deviation. IQR: inter quartile range.
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analysis was performed of CD patients referred with an unsatis-
factory response to botulinum toxin treatment.
2. Methods
Forty consecutive patients with idiopathic CD referred to our specialized centre
between 2003 and 2009 were studied. The following inclusion criteria were chosen:
1) diagnosis of CD, 2) referred because of unsatisfactory response to botulinum toxin
treatment and 3) pEMG performed in our centre before treatment. Exclusion criteria
were: 1) an expressed suspicion in our centre of a psychogenic cause for the torti-
collis and 2) insensitivity to botulinum toxin conﬁrmed by a negative extensor
digitorum brevis (EDB) test [11].
To obtain the relevant information, patient charts and all the available corre-
spondence were studied. Informationwas obtained about disease duration, number
of previous treatments, muscles selected for treatment, dosages in the referring
hospital and in our centre, performance of pEMG in the referring hospital and side
effects. If patients received Botoxmouse-units (MU), the equivalent in Dysport-units
was calculated using a conversion ration of 1:3. The number of treatments in the
referring hospital was estimated assuming an average of 4 treatments per year if the
exact number was unknown.
As outcome measures we retrieved Tsui scores (an objective severity scale
ranging from 0 to 25 points [12]), VAS scores (a subjective ten point severity scale)
and patients subjective evaluations assessed at the ﬁrst visit in our centre, after 12
weeks and after one year of treatment. Patient’s subjective evaluations reﬂected the
perceived effect of the previously received treatment and were scored by one of the
investigators (S.N.) as good effect (1), moderate effect (2) or no effect (3). In addition,
we assessed the ﬁnal treatment outcome in our centre based on the last entries in
the patient charts. The ﬁnal outcomewas scored as follows: continuing of botulinum
toxin treatment in our centre or with their referring neurologist with a good
(1), reasonable (2) or poor (3) response, referral to a neurosurgeon for Deep Brain
Stimulation (DBS) (4), withdrawal from treatment (5) or unknown (6). In case of
ongoing treatment (1e3) the general treatment response was based on the average
subjective evaluations from the last treatments. A treatment response was qualiﬁed
as good (1) if there was a good treatment response in the vast majority of the
treatments. A treatment response was qualiﬁed as reasonable (2) when response
was good in at least half of the treatments and treatment response was qualiﬁed as
poor (3) when the response was moderate or poor in the majority of the treatments.
Finally, we attempted to reach all patients to ask their ﬁnal personal opinion
about the overall effect of referral to our centre on their treatment response. Their
response was scored as clear improvement (1), some improvement (2), no
improvement (3) or worsening (4) of treatment response.
2.1. Treatment protocol
Before the ﬁrst botulinum toxin treatment in our centre pEMG was performed,
using needle electrode recordings with auditory and visual feedback. Based on
clinical evaluation combined with pEMG results, dystonic muscles were selected for
BoNT treatment. All patients received BoNT every three months. A dilution of 200
MU dysport per millilitre was used and injections were divided over 1e3 injection
sites per muscle. During all treatment sessions EMG guidance with auditory/visual
feedback was used for accurate needle placement in target muscles. All patients
were treated by an experienced team consisting of 3 movement disorder specialists
and 2 specialized dystonia nurse practitioners. Treatment protocols and injections
schedules were always determined by a movement disorder specialist. Before each
subsequent treatment patients were asked for side effects experienced.
3. Statistical analysis
All statistics were performed using SPSS 16.0. Baseline charac-
teristics are presented using mean and SD for normally distributed
data and median and inter quartile range (IQR) for not normally
distributed data. The Wilcoxon Signed Ranks Test was used to
compare the mean Botulinum toxin dose patients received before
referral with the dose given at the ﬁrst and at the last treatment
session in our centre. Longitudinal analyzes were used to inves-
tigate the improvement of the Tsui and subjective scores. For the
longitudinal analyzes only patients were included with data on all
the time points. The Wilcoxon Signed Ranks Test was used to
compare the subjective scores before treatment to the scores after
one year of treatment and the paired sample t test was used to
compare the Tsui scores. To investigate the association between the
use of pEMG in the referring hospital and a favourable outcome in
our centre the Pearson’s chi squared test and the Fisher exact testwere used. A favourable outcome was deﬁned as a reasonable or
good ﬁnal treatment outcome or a clear subjective overall
improvement. Finally, to compare the proportions of primary non-
responders and secondary non-responders with a favourable out-
come, the Pearson’s chi squared test was used.
4. Results
Forty three consecutively referred patients matching all the
inclusion criteria were identiﬁed. Two patients had a negative EDB
test and were excluded. One patient died and his patient chart
could not be retrieved, so he was also excluded. The remaining 40
patients were included for analysis. Baseline characteristics are
presented in Table 1.
5. Dosage of botulinum toxin
The dosage of botulinum toxin received during the last treat-
ment in the referring centre could be found for only 21 cases. Ten
patients received injections with Botox and 11 with Dysport with
a median (converted) dose of 375 MU(IQR 285e500). The differ-
ence between the last dosage at the referring centre (375 units) and
the ﬁrst dosage in our centre (median 355 units) was not statisti-
cally signiﬁcant (p > 0.05). The dosage signiﬁcantly increased
gradually from 355 units (IQR 282e450) at the ﬁrst treatment in
our centre to 400 units (IQR 350e470) after one year (p < 0.05).
However, the last dosage received at the referring centre and the
dosage after one year of treatment in our centre did not differ
signiﬁcantly (p > 0.05) (Fig. 1).
6. Muscle selection
In 25 of the 40 (63%) patients the selection of muscles for
treatment in the referring centre could be retrieved. In 24 of these
25 patients (96%) the selection of muscles changed after pEMG
evaluation and clinical evaluation in our centre. The median
number of mutations in muscle selection was 4 (IQR 3e5). The
median number of additional muscles that were injected was 2
(IQR 1.5e3.5) and the median number of muscles that were no
longer treated after pEMG evaluationwas 1 (IQR 1e2). The muscles
that were most frequently added to the muscles selected for
treatment were the splenius (SPL) and the semispinalis (SESP)
muscles. The levator scapulae (LS) and the trapezius (TPZ) muscles
were most frequently removed from the selection.
7. Tsui, VAS and subjective scores
The mean Tsui score at time of referral was 11.2 (N ¼ 36). After
one year 29 patients still continued BoNT treatment in our centre.
After excluding cases withmissing values, longitudinal analysis was
performed on the Tsui scores (N ¼ 24) and on the subjective scores
(N ¼ 23). The mean Tsui score in these patients improved from
a baseline score of 11.2 at time of referral to 10.3 after 12 weeks (8%
improvement). After one year of treatment in our centre the Tsui
Fig. 2. Results. **: Signiﬁcantly different from baseline score (p-value < 0.01), ***: signiﬁcan
DBS: Deep brain stimulation.
Fig. 1. Dosage. Ns: not signiﬁcant (p > 0.05) *: statistically signiﬁcant (p < 0.05) O:
outlier * extreme outlier.
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p < 0.01). The subjective scores signiﬁcantly improved after 12
weeks (p < 0.01) and even further after one year (p < 0.001) of
treatment (Fig. 2). Longitudinal analysis could not be performed on
the VAS scores as for only a small number of patients data was
available on all time points (Table 2).8. Final treatment outcome
On their last visit, on average 2.4 year (range 0.5e6) after the
ﬁrst treatment in our centre, 32.5% of the patients still continued
botulinum toxin treatment with a good response, 27.5% continued
with a reasonable response and 2.5% continued with a poor
response. Twenty percent of the patients withdrew from treatment,
15% were referred for Deep Brain Stimulation (DBS) and for one
patient the treatment outcome was unknown.
Thirty-four patients (85%) could be reached to ask their personal
ﬁnal opinion about the effect of referral on their treatment
response. Seventeen patients (50%) thought that their response to
botulinum toxin treatment improved and 11 of these 17 patients
reported a clear improvement. Sixteen patients (47%) thought there
was no difference in treatment response after continuing treatment
in our centre and one patient thought that his response had
decreased.tly different from baseline score (p-value < 0.001) error bars: 95% conﬁdence interval.
Table 2
Results.
Pat
nr
Predominant
movement
Primary/
secondary
non-responders
Age Duration
disease
(years)
Number
of previous
treatments
Last dosage
referring
centre (MU)
Previous
polymyography
Tsui Visual analogue scale Subjective scoresa Final
treatment
outcomeb
Overall
subjective
evaluationc
First
dose
(MU)
Second
12 wks
(MU)
Dose
year
(MU)
Baseline 12 wks Year Baseline 12 wks Year Baseline 12 wks Year
1 Antecollis P 65 10 20 8 3 3 IV 3 140 260
2 Rotation (r) 67 3 16 Y 10 12 9 4 6 2 1 I 3 400 360 360
3 Rotation (l)/
lateroﬂexion (r)
P 60 15 2 8 12 8 8 2 3 3 V 490 710 700
4 Rotation (r) P 66 11 20 270 N 12 9 3 2 1 I 1 140 140 340
5 Rotation (r) S 50 10 2 500 12 12 12 9 3 1 1 I 480 520 560
6 Lateroﬂexion (L) P 47 2 2 200 N 14 10 14 3 3 2 I 1 260 370 380
7 Rotation (l) P 59 5 5 380 N 13 9 8 3 3 2 II 1 400 480 480
8 Retrocollis S 48 14 36 N 16 16 7 8 8 2 1 II 1 330 350 400
9 Rotation (l) S 44 13 20 675 Y 15 12 12 9 10 10 3 2 1 II 2 450 280 400
10 Rotation (r)/
lateroﬂexion (r)
S 60 28 12 11 8 8 8 2 3 3 I 270 320 400
11 Rotation (r) P 42 1.5 2 500 10 6 8 8 8 6 3 1 1 II 450 390 490
12 Lateroﬂexion (r) P 50 7 2 780 N 18 20 10 9 3 3 2 I 1 300 600 410
13 Rotation (r)/
lateroﬂexion (l)
P 65 2 5 140 Y 8 8 10 3 3 V 3 260 200
14 Rotation(r) P 28 2 2 N 14 12 7 9 3 2 1 I 1 370 490 460
15 Rotation (l) S 48 0.75 2 450 N 10 10 12 7 2 3 I 1 390 370 460
16 Rotation(r)/
retroﬂexion
P 67 3 3 360 N 6 10 7 8 3 2 2 V 3 410 430 430
17 Rotation (r) P 48 18 N 5 6 6 7 3 2 II 2 200 280 350
18 Rotation (l)/
lateroﬂexion(r)
P 39 1 2 400 Y 14 3 V 3 350
19 Rotation (l) S 54 2 8 375 N 8 4 4 5 2 1 1 II 1 420 460 370
20 Rot (l) lat (r) P 52 15 1200 N 8 6 8 3 3 1 I 1 450 450 470
21 Rotation (l) P 75 30 3 300 12 8 9 7 6 3 1 2 III 3 250 260 290
22 Rotation (l) P 75 8 24 16 18 9.5 9 2 3 IV 3 490 680
23 Rotation (l) P 74 2 2 500 N 10 8 10 7.5 8 3 3 1 I 1 510 570 600
24 Rotation (l) S 65 12 48 450 11 7 6.5 2 2 II 3 350 350
25 Rotation (r)/
anteroﬂexion
P 63 3 6 N 12 7 8.5 7.5 2 2 2 IV 3 470 370 240
26 Rotation (r) S 61 4 9 250 N 12 9 12 2 1 2 II 2 330 330 340
27 Rotation (r) P 33 10 3 11 2 VI 400
28 Anteroﬂexion S 55 15 20 165 12 12 2 2 V 3 300 260
29 Rotation (l) 42 15 12 330 Y 2 IV 4 360
30 Rotation (l) S 59 1.5 6 320 N 8 8 2 1 II 2 320 440
31 Retroﬂexion P 64 4 2 Y 12 12 10 3 3 1 II 2 200 280 400
32 Rotation (l)/
lateroﬂexion (r)
P 74 5 2 N 14 14 9 8 9 3 2 2 I 490 600 580
33 Rotation (l)/
lateﬂexion (l)
S 50 10 36 N 10 12 10 10 8 10 3 2 2 IV 3 450 420 360
34 Rotation (l) S 51 2 2 N 16 12 10 3 3 IV 3 380 410
35 Rotation (l)/
lateroﬂexion (r)
P 68 10 7 12 2 2 V 3 340
36 Rotation (r)/
lateroﬂexion (l)
42 9 2 360 N 10 9 8 4 8 2 2 1 II 1 500 400 360
37 Anteroﬂexion P 72 4 4 N 12 10 10 7 3 3 2 2 I 3 240 300 300
38 Rotation (l) P 48 3 4 Y 6 13 8 8 2 1 1 I 2 280 310 350
39 Lateroﬂexion (L) P 56 19 Y 13 7 3 2 V 3 310 380
40 Retroﬂexion S 68 30 8 7 9 3 2 V 3 290 320
Average 56 9.0 9.7 424 11.2 10.3 9.1 8.2 7.8 7.3 2.6 2.2 1.6 355.5 392.8 417.8
MU: Mouse-units, wks: weeks, (r): right, (l): left.
a Subjective scores: 1: good effect, 2: moderate effect, 3: no effect.
b Roman numerals: I Good response, II reasonable response, III poor response, IV DBS Deep Brain Stimulation, V quit treatment, VI unknown.
c Numerals overall subjective evaluation:1 clear improvement, 2 some improvement, 3 no improvement, 4 deterioration.
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Information about the use of pEMG in the referring centre was
available for 27 patients. Eight of these 27 underwent pEMG before
treatment in the referring centre whereas 19 patients did not un-
dergo pEMG. The eight patients that underwent pEMG in the
referring centre had relatively little beneﬁt from referral to our
centre. The proportion of patients with a ‘good’ to ‘reasonable’ ﬁnal
treatment result was smaller in this group (Odds Ratio: 0.267,
p > 0.05). Similarly, a signiﬁcantly smaller proportion of this group
subjectively reported a clear improvement after referral to our
centre (p < 0.01) compared to the patients that did not undergo
pEMG in their referring centre.
10. Primary vs secondary non-responders
The proportion of primary non-responders with a good or rea-
sonable ﬁnal treatment result was slightly smaller compared to
secondary non-responders (OR: 0.44 (p > 0.05)). However,
a slightly bigger proportion of the primary non-responders sub-
jectively reported a clear improvement after referral to our centre
(OR: 1.88 (p > 0.05)). These differences were not statistically
signiﬁcant.
11. Side effects
After the ﬁrst treatment in our centre 17 patients (42.5%)
experienced side effects. Eight patients (20%) complained of pain, 5
patients experienced symptoms of mild dysphagia (12.5%), 5 pa-
tients complained of muscle weakness (12.5%) and 2 patients (5%)
experienced another side effect (ﬂu-like symptoms in one patient
and difﬁculty to open his mouth in another patient). All side effects
were mild, resolved spontaneously and additional interventions
were never required. No data were available for side effects from
the referring hospitals.
During the following year of treatment in our centre one patient
had an exacerbation of pre-existing swallowing difﬁculties after
botulinum toxin treatment and was admitted for 2 days at our
hospital for evaluation. No additional interventions, like enteral
nutrition, were needed and he left the hospital in a good condition.
12. Discussion
A substantial amount of CD dystonia patients with an unsatis-
factory response to botulinum toxin treatment improved after
polymyography and subsequent botulinum toxin treatment in our
centre. A recent review has shown that polymyographic analysis of
muscle involvement in CD might improve the response to botuli-
num toxin treatment in CD, especially in more complex cases, but
evidence is scarce [10]. Cordivari et al. [13] have shown that pEMG
might restore responsiveness in secondary non-responders with-
out antibodies against BoNT.
In our study we were able to obtain a reasonable to good ﬁnal
treatment result in 60% of the patients with a previous unsatis-
factory response. In line with this, 50% of the patients reported
subjectively, that referral to our centre improved their response to
botulinum toxin treatment. The Tsui and subjective scores both
improved after a single treatment session, and even further after
one year of treatment. Interestingly, the small proportion of pa-
tients that underwent pEMG already before coming to our centre
had relatively little beneﬁt from referral to our centre, supporting
the hypothesis of a positive value of additional pEMG. The inﬂuence
of the expertise of our tertiary referral centre on the improved
treatment response cannot be ruled out. Also, the inﬂuence of EMG
guidance for accurate needle placement during BoNT injections canpartly explain the positive effect. Finally, the increasing dosage
might be explanatory for some of the observed improvement
response after one year. However, the increasing treatment
response started already after the ﬁrst treatment in our centre
when a lower dose was given compared to the referring centre.
There are some limitations to our retrospective study. Eleven of the
forty patients were treated for less then one year in our centre and
therefore no data were available for all the time points. A sub-
stantial part of these eleven patients stopped treatment or were
referred for DBS. This is a source of bias towards a favourable
outcome of the per protocol analysis that was performed to
investigate the improvement on the Tsui and subjective scores after
one year of treatment. However, the observed improvement in the
remaining patients signiﬁes that a substantial part of the initial
non-responders had clearly improved.
In addition there were some missing data, especially in the VAS
scores, that could not be retrieved because they were not recorded
in the patient charts. We expect these missing data to be rather
random and not a substantial source of bias.
Another possible confounding factor might be the time interval
between the assessment of the baseline scores and the last treat-
ment patients had received at the referring centre which was often
longer than the standard 12 weeks interval between treatment and
evaluation of the treatment in our centre. This may have inﬂuenced
the baseline Tsui scores since they evaluate the severity of the
complaints at the time of assessment and this could have biased the
observed improvement on these scores. However, subjective scores
also indicated a more favourable response in our centre compared
to earlier treatment. Finally, some patients were previously treated
with Botox and received Dysport in our centre. Although unlikely,
as they are both type A forms of botulinum toxin, it cannot be
excluded that this switch accounts for part of the favourable
response in some patients. This has previously been suggested for
patients suffering from blepharospasm and hemiﬁcial spasm [14].
Despite the above mentioned limitations, the results are in line
and indicate an improved treatment response in a tertiary centre in
a substantial part of the patients. We speculate that pEMG is helpful
in muscle selection and improves the response to botulinum toxin
treatment in CD patients. It has been suggested that in the majority
of CD patients a good clinical response can be obtained with clinical
evaluation alone and in these patients the use of pEMG cannot be
justiﬁed [15]. We hypothesise that even in patients with a good
response, treatment results can be further improved with pEMG.
However, there is insufﬁcient evidence to recommend the standard
use of pEMG in all CD patients. Nevertheless, in patients with an
unsatisfactory response, inadequate muscle selection might be an
important cause for treatment failure and for these patients we
recommend the use of pEMG to improve treatment response. More
prospective randomized trials are required to conﬁrm the value of
pEMG.
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